Compare MGN & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGN | ADVB |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | Malaysia | United States |
| Employees | 4 | 31 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.4M |
| IPO Year | N/A | N/A |
| Metric | MGN | ADVB |
|---|---|---|
| Price | $0.10 | $5.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.5M | 10.1K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.33 | ★ $1.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.19 |
| 52 Week High | $5.18 | $7.70 |
| Indicator | MGN | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 34.41 | 56.22 |
| Support Level | N/A | $3.81 |
| Resistance Level | $0.16 | $5.59 |
| Average True Range (ATR) | 0.02 | 0.53 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 5.83 | 60.22 |
Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.